Evaxion Biotech expands preclinical bacterial vaccine pipeline, EVX-B3

Evaxion Biotech announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations. To develop an effective vaccine, Evaxion has initiated discovery activities for EVX-B3 using both its EDEN and RAVEN AI platforms to identify protective antigens capable of eliciting both a humoral and cellular response to the pathogen. EVX-B3 aims to address a serious global medical issue, targeting a pathogen associated with repeated infections, increasing incidence and often serious medical complications, and for which no vaccines are currently available. The project will be a collaborative and co-funded effort between the two companies. Evaxion’s Chief Scientific Officer, Birgitte Rono, states: “We are thrilled to announce our upcoming collaboration, aimed at jointly investigating the capabilities of our AI platforms to design a groundbreaking vaccine targeting this specific pathogen. We strongly believe that this collaboration will further validate the power of AI to benefit global health through the design of unique vaccines against serious medical conditions.”